Institutional members access full text with Ovid®

Share this article on:

ATG-Fresenius S Combined With Cyclosporine A: An Effective Immunosuppressive Therapy for Children With Aplastic Anemia

Luo, Cheng-Juan MD; Gao, Yi-Jin PhD; Tang, Jing-Yan PhD; Zhu, Xiao-Hua MD; Xue, Hui-Liang MD; Lu, Feng-Juan MD; Pan, Ci MD; Jiang, Hua PhD; Luo, Chang-Ying PhD; Ye, Qi-Dong PhD; Zhou, Min MD; Chen, Jing PhD

Journal of Pediatric Hematology/Oncology: July 2014 - Volume 36 - Issue 5 - p 374–378
doi: 10.1097/MPH.0000000000000170
Original Articles

For the first time, we conducted a 2-center retrospective study to show the efficacy of antithymocyte globulin (ATG)-Fresenius S plus cyclosporine treatment of children with severe aplastic anemia. From March 1997 to May 2011, a total of 124 patients (median age, 7.5 y; range, 1.5 to 16 y) from 2 centers with acquired AA treated with an immunosuppressive therapy (IST) regimen, consisting of ATG-Fresenius S (5 mg/kg per day for 5 d) and cyclosporine, were enrolled. The response rate was 55.6%. The median time between IST and response was 6 (0.5 to 18) months. After a median follow-up time of 29 (6 to 153) months, the rates of relapse and clonal evolution were 3.2% and 0.8%, respectively. Overall, 17 patients (13.7%) died in this study: 14 resulted from sepsis, 1 resulted from intracranial hemorrhage, 1 occurred after hematopoietic stem cell transplantation, and 1 resulted from clonal disease progression. The 5-year overall survival rate for the entire cohort was 74.7%. IST responders had a better survival rate (100%) than nonresponders (70.7%). The use of ATG-Fresenius S plus cyclosporine as a first-line immunosuppressive treatment appeared to be effective for children with severe aplastic anemia in our study. ATG-Fresenius S could be another option in the treatment arsenal, especially in countries where the other ATG products are harder to acquire.

*Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University

Children’s Hospital, Shanghai Medical College, Fudan University, Shanghai, China

C-J.L. and Y-J.G. contributed equally.

Approval of the retrospective study was obtained from the ethical committee of the 2 participating hospitals. Informed consent from study participants were waived because the data analyses were from spread sheets.

Contributors: C-J.L. and Y-J.G. wrote the main body of the article. J.C. contributed to the project conception, data collection, data interpretation, and manuscript revision. J-Y.T., X-H.Z., H-L.X., F-J.L., C.P., H.J., C-Y.L., Q-D.Y., and MZ contributed to the data collection and interpretation.

The authors declare no conflict of interest.

Reprints: Jing Chen, PhD, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China (e-mail:

Received September 11, 2012

Accepted April 1, 2014

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.